OncoMatch/Clinical Trials/NCT06963216
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Is NCT06963216 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Coagadex(R) for acquired factor x deficiency.
Treatment: Coagadex(R) — The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Cannot have received: factor X containing product
Any factor X containing product taken within 2 weeks of first Coagadex® administration
Cannot have received: anticoagulant therapy
Exception: antiplatelets permitted
On anticoagulant therapy (not antiplatelets)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Phoenix, Arizona
- Mayo Clinic Rochester · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06963216 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior factor X containing product, anticoagulant therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify